Publication: Tight control for Crohn-s disease with adalimumab-based treatment is cost-effective: an economic assessment of the CALM trial
Loading...
Program
relationships.isAuthorOf
Author
Panaccione, Remo
Colombel, Jean-Frederic
Travis, Simon P. L.
Bossuyt, Peter
Baert, Filip
Vanasek, Tomas
Danalioglu, Ahmet
Advisor
Date
Language
Type
Publisher
Journal Title
Journal ISSN
Volume Title
Abstract
Objective To evaluate the cost-effectiveness of an inflammatory biomarker and clinical symptom directed tight control strategy (TC) compared with symptom-based clinical management (CM) in patients with Crohn-s disease (CD) naive to immunosuppressants and biologics using a UK public payer perspective.
Description
Source
Keywords
Keywords
Citation
Panaccione R., Colombel J., Travis S. P. L. , Bossuyt P., Baert F., Vanasek T., Danalioglu A., Novacek G., Armuzzi A., Reinisch W., et al., -Tight control for Crohn-s disease with adalimumab-based treatment is cost-effective: an economic assessment of the CALM trial-, GUT, cilt.69, ss.658-664, 2020